Moreover, these and other data indicate that targeting of TK signaling or relevant downstream signaling molecules will reduce the aberrant inflammatory cytokine production not only in PMF, ET, and PV but also in other MPN. The gene discussed is TKT; the disease is myeloproliferative disorder.